The Emerging Role of Checkpoint Inhibitor Therapy in Hodgkin Lymphoma

Free article

Comment

Anita Kumar. Oncology (Williston Park). 2016.

Free article

. 2016 Oct 15;30(10):921-2.

No abstract available

Comment on

Checkpoint Inhibition in Hodgkin Lymphoma: Saving the Best for Last?
Lin RJ, Diefenbach CS. Lin RJ, et al. Oncology (Williston Park). 2016 Oct 15;30(10):914-20. Oncology (Williston Park). 2016. PMID: 27753058 Free PMC article. Review.

[New therapy outlooks in Hodgkin lymphoma].
Rossi C, Casasnovas RO. Rossi C, et al. Bull Cancer. 2017 Feb;104(2):182-194. doi: 10.1016/j.bulcan.2016.11.005. Epub 2017 Jan 12. Bull Cancer. 2017. PMID: 28088309 Review. French.
Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma.
Bennani-Baiti N, Thanarajasingam G, Ansell S. Bennani-Baiti N, et al. Expert Rev Clin Immunol. 2016 Jun;12(6):673-9. doi: 10.1586/1744666X.2016.1147350. Epub 2016 Feb 17. Expert Rev Clin Immunol. 2016. PMID: 26818843 Review.
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
Falchi L, Sawas A, Deng C, Amengual JE, Colbourn DS, Lichtenstein EA, Khan KA, Schwartz LH, O'Connor OA. Falchi L, et al. J Hematol Oncol. 2016 Nov 30;9(1):132. doi: 10.1186/s13045-016-0363-1. J Hematol Oncol. 2016. PMID: 27899158 Free PMC article.
Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E, Younes A. Matsuki E, et al. Curr Treat Options Oncol. 2016 Jun;17(6):31. doi: 10.1007/s11864-016-0401-9. Curr Treat Options Oncol. 2016. PMID: 27193488 Free PMC article. Review.
Checkpoint Inhibition in Hodgkin Lymphoma - a Review.
Bröckelmann PJ, Engert A. Bröckelmann PJ, et al. Oncol Res Treat. 2017;40(11):654-660. doi: 10.1159/000481800. Epub 2017 Oct 20. Oncol Res Treat. 2017. PMID: 29065424 Review.